| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Hospital & Healthcare Services
|
Compare with Industry peers |
| Website | http://www.tejnaksh.com | |
| Market Cap | 60.53 Cr. | |
| Enterprise Value(EV) | 61.99 Cr. | 2023-09 |
| Financial Indicators | ||
|---|---|---|
| Earnings per share (EPS) | 0.50 | Trailing Twelve Months Ending 2023-09 |
| Price-Earning Ratio (PE) | 59.23 | Trailing Twelve Months Ending 2023-09 |
| Industry PE | 63.07 | Trailing Twelve Months Ending 2023-09 |
| Book Value / Share | 11.09 | Trailing Twelve Months Ending 2023-09 |
| Price to Book Value | 2.69 | Calculated using Price: 29.80 |
| Dividend Yield | 0.00 | Period Ending 2023-03 |
| No. of Shares Subscribed | 2.03 Cr. | 20,313,600 Shares |
| FaceValue | 5 | |
| About Tejnaksh Healthcare Ltd. | ||
| The company is an integrated healthcare delivery service provider, committed to delivering quality healthcare services to its patients in modern facilities. Its operations are divided across four key vertical streams in healthcare delivery, namely - “Pediatric Urologyâ€, “Adult Urology (Male, Female)â€, “Andrology and Sexual Dysfunction†and “Nephrology, Dialysis and Renal Transplantâ€. It offers a gamut of more than 65 healthcare services under these streams. A base of over 65 employees and consultants supports its healthcare facility network. The company's healthcare facilities use advanced technology and its doctors, nurses and other healthcare professionals follow treatment protocols that match international standards. A majority of its healthcare facilities provide secondary, tertiary and quaternary healthcare services to patients. Some of its healthcare facilities provide super speciality quaternary healthcare to patients in key specialty areas such as Pediatric Urology and Adult Urology (Male, Female). | ||
| 1 Day |
|
-0.67% |
| 1 Week |
|
-1.62% |
| 1 Month |
|
-1.88% |
| 3 Month |
|
-12.74% |
| 6 Month |
|
-13.50% |
| 1 Year |
|
-49.96% |
| 2 Year |
|
-47.49% |
| 5 Year |
|
-6.88% |
| 10 Year |
|
| 8 years | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | 2023-03 | |
| Return on Equity (%) | 21.17 | 26.68 | 34.98 | 26.93 | 15.10 | 12.71 | 15.05 | 8.57 | |
| Return on Capital Employed (%) | 34.00 | 29.35 | 32.66 | 27.59 | 17.78 | 14.20 | 17.22 | 11.36 | |
| Return on Assets (%) | 19.32 | 16.96 | 17.97 | 14.93 | 9.10 | 8.36 | 10.38 | 5.89 |
| Particulars | 9 years | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09* Rs. Cr. |
| Shh. Funds | 6 | 8 | 10 | 13 | 15 | 17 | 20 | 22 | 23 | |
| Non Curr. Liab. | 0 | 7 | 6 | 6 | 7 | 5 | 7 | 7 | 7 | |
| Curr. Liab. | 0 | 1 | 3 | 2 | 2 | 2 | 2 | 2 | 2 | |
| Minority Int. | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | ||
| Equity & Liab. | 7 | 16 | 20 | 22 | 25 | 25 | 30 | 31 | 32 | |
| Non Curr. Assets | 6 | 14 | 17 | 18 | 18 | 21 | 25 | 25 | 25 | |
| Curr. Assets | 1 | 2 | 3 | 5 | 7 | 3 | 5 | 6 | 6 | |
| Misc. Exp. not W/O | ||||||||||
| Total Assets | 7 | 16 | 20 | 22 | 25 | 25 | 30 | 31 | 32 |
| Particulars | 9 years | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09 Rs. Cr. TTM |
| Net Sales | 5 | 7 | 14 | 20 | 17 | 12 | 13 | 12 | 11 | |
| Other Income | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | |
| Total Income | 5 | 7 | 15 | 21 | 17 | 12 | 13 | 12 | 12 | |
| Total Expenditure | -2 | -4 | -9 | -16 | -13 | -8 | -8 | -8 | -9 | |
| PBIDT | 2 | 3 | 6 | 6 | 4 | 4 | 5 | 4 | 3 | |
| Interest | 0 | -1 | -1 | -1 | -1 | 0 | -1 | -1 | ||
| Depreciation | 0 | 0 | 0 | -1 | -1 | -1 | -1 | -1 | -1 | |
| Taxation | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | |
| Exceptional Items | ||||||||||
| PAT | 1 | 2 | 3 | 3 | 2 | 2 | 3 | 2 | 1 | |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||
| Share Associate | 0 | |||||||||
| Other Related Items | ||||||||||
| Consolidated Net Profit | 1 | 2 | 3 | 3 | 2 | 2 | 3 | 2 | 1 | |
| Adjusted EPS | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Particulars | 8 years | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
| Cash Fr. Operatn. | 4 | 2 | 4 | 3 | 1 | 1 | 9 | 2 | |
| Cash Fr. Inv. | -3 | -8 | -3 | -2 | -1 | 2 | -11 | -1 | |
| Cash Fr. Finan. | 0 | 6 | -1 | -2 | 0 | -3 | 2 | -1 | |
| Net Change | 0 | 1 | 1 | -1 | 0 | 0 | 0 | 0 | |
| Cash & Cash Eqvt | 0 | 1 | 2 | 1 | 1 | 1 | 1 | 1 |
|
Fri, 01 Dec 2023
Announcement Under Regulation 30 - 7Th Innovation Patent Granted Dr Ashish Rawandale Managing Director of Company have granted Patent for Percutaneous Access Device..Please find attached letter for more detail |
|
Sat, 11 Nov 2023
Submission Of Un-Audited Financial Results (Standalone & Consolidated) For The Quarter Ended On 30Th September 2023. Please find enclosed financial statement (Consolidated and Standalone) for the quarter and half year ended 30th September 2023 |
|
Sat, 11 Nov 2023
Board Meeting Outcome for Outcome Of Board Meeting In Accordance With SEBI (Listing Obligations And DisclosureRequirements) Regulations 2015 In continuation of our Letter dated 2nd November 2023 we wish to inform you that a meeting of theBoard of Directors of the Company was held on Saturday 11th November 2023 at A 601 Floor No.6 Kailash Business Park Veer Savarkar Marg Vikroli - West Mumbai - 400079 at 4.00 p.m. and hastransacted the following:-1. Considered and approved Un-Audited Financial Results (Standalone & Consolidated) for thequarter ended on 30th September 2023 and took note of Limited Review Report thereon interms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015;The meeting of Board of Directors commenced at 4.00 p.m. and concluded at 5.00 pm |
| Fri, 08 Dec 2023 |
Opening at High
|
Close Within 52 Week Low Zone
|
High Decrease in 3 Months
|
High Decrease in 1 Year
|
MFI Below 20
|
Equities
M.F.
Sectors
StockEdge Social